Esperion Therapeutics inc   (ESPR)
Other Ticker:  
Price: $2.5500 $0.04 1.594%
Day's High: $2.56 Week Perf: -3.04 %
Day's Low: $ 2.45 30 Day Perf: 19.16 %
Volume (M): 2,977 52 Wk High: $ 5.56
Volume (M$): $ 7,590 52 Wk Avg: $1.68
Open: $2.52 52 Wk Low: $0.70

 Market Capitalization (Millions $) 263
 Shares Outstanding (Millions) 103
 Employees -
 Revenues (TTM) (Millions $) 116
 Net Income (TTM) (Millions $) -209
 Cash Flow (TTM) (Millions $) -43
 Capital Exp. (TTM) (Millions $) 0

Esperion Therapeutics Inc
Esperion Therapeutics Inc. is a biopharmaceutical company based in the United States that specializes in developing and commercializing innovative therapies for the treatment of cardiovascular diseases. The company's primary focus is on developing oral, targeted therapies designed to lower elevated levels of low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia, a condition associated with an increased risk of cardiovascular disease. Esperion Therapeutics' lead product candidate is bempedoic acid, which has shown promising results in lowering LDL-C levels and improving cardiovascular outcomes in clinical trials. The company is committed to addressing the unmet medical needs of patients and aims to provide safe and effective therapeutic options for the prevention and treatment of cardiovascular diseases.

   Company Address: 3891 Ranchero Drive, Suite 150 Ann Arbor 48108 MI
   Company Phone Number: 887-3903   Stock Exchange / Ticker: NASDAQ ESPR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Esperion Therapeutics Inc

Esperion Therapeutics Inc Sees Revenue Growth and Reduction in Losses in Fiscal Q3 2023

As a financial journalist for the , I have been closely monitoring the recent financial results of Esperion Therapeutics Inc, a major player in the pharmaceutical industry. The company's fiscal three months ending December 31, 2023, showed a remarkable revenue growth of 71.378% to $32.25 million, leading to a decrease in losses to $-0.36 per share from $-0.48 in the previous year. Despite a slight decrease in revenue in the third quarter, the company managed to improve its earnings per share (EPS) from $-0.37 per share.
However, the fourth quarter of 2023 saw Esperion Therapeutics Inc facing a net shortfall of $-56.344 million, slightly higher than the previous year. The company also witnessed an increase in inventories and supplies, indicating a rise in demand. Accounts receivable also saw a noticeable increase, reaching $48.5 million, further highlighting the company's growth trajectory.

Financing Agreement

Esperion Accelerates Growth with Inducement Grants to Attract Top Talent

Published Fri, Feb 16 2024 9:30 PM UTC

In a bid to foster continued innovation and attract top-tier talent, Esperion, a leading pharmaceutical company based in Ann Arbor, Michigan, has recently made a significant move. On February 13, 2024, the company granted 66 new employees a total of 204,900 restricted stock units (RSUs) under the Esperion 2017 Inducement Equity Incentive Plan. This latest developme...


Esperion Therapeutics Raises $97.8 Million in Successful Public Offering to Advance Cholesterol Management Paradigm

Published Tue, Jan 23 2024 9:00 PM UTC

Esperion Therapeutics Successfully Closes Public Offering, Raising $97.8 Million
Ann Arbor, Michigan - Esperion Therapeutics, Inc. (Nasdaq: ESPR), a leading pharmaceutical company specializing in lipid management, has announced the successful completion of its underwritten public offering. The offering, which included 65,205,000 shares of common stock, raised approximate...

Financing Agreement

Esperion's Milestone $85.1 Million Common Stock Public Offering Paves the Way for Revolutionary Medical Solutions

Published Fri, Jan 19 2024 2:17 AM UTC

Esperion Announces Successful Pricing of $85.1 Million Common Stock Public Offering, Reinforcing Financial Strength
ANN ARBOR, Mich., Jan. 18, 2024 - Esperion Therapeutics, Inc. (Nasdaq: ESPR) has recently unveiled the pricing details of its highly anticipated underwritten public offering. This transformative event marks a significant milestone for the biopharmaceutical ...

Financing Agreement

Esperion Therapeutics: Revolutionizing Cardiovascular Care Through Innovative Public Offering

Published Thu, Jan 18 2024 9:00 PM UTC

Esperion Therapeutics Announces Public Offering as it Continues to Pioneer Cardiovascular Therapies
ANN ARBOR, Mich., Jan. 18, 2024 - Esperion Therapeutics, Inc. (Nasdaq: ESPR), a leading pharmaceutical company focused on innovative cardiovascular therapies, revealed its plans today to conduct an underwritten public offering of shares of its common stock. This announceme...


Esperion Therapeutics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Esperion Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Esperion Therapeutics inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com